Filtered By:
Specialty: Rheumatology
Condition: Arthritis

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 260 results found since Jan 2013.

Usefulness of CHA2DS2 ‐VASc score to predict mortality and hospitalization in patients with inflammatory arthritis
ConclusionCHA2DS2‐VASc‐score accurately identifies in the mid‐term patients in sinus rhythm with RA/AS/PsA at different risks for CV and non‐CV mortality and hospitalization.
Source: International Journal of Rheumatic Diseases - December 18, 2019 Category: Rheumatology Authors: Giovanni Cioffi, Ombretta Viapiana, Giovanni Orsolini, Luca Idolazzi, Elena Fracassi, Federica Ognibeni, Andrea Dalbeni, Davide Gatti, Antonio Carletto, Angelo Fassio, Maurizio Rossini, Alessandro Giollo Tags: ORIGINAL ARTICLE Source Type: research

Role of Nonsteroidal Antiinflammatory Drugs in the Association Between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study
ConclusionThe findings of this first study to evaluate the mediating role of NSAIDs in the relationship between OA and CVD suggest that NSAID use contributes substantially to the OA –CVD association.
Source: Arthritis and Rheumatology - September 4, 2019 Category: Rheumatology Authors: Mohammad Atiquzzaman, Mohammad E. Karim, Jacek Kopec, Hubert Wong, Aslam H. Anis Tags: Original Article Source Type: research

AHA News: Here's Why Stroke Survivors Need to Pay Attention to Bone Health
Title: AHA News: Here's Why Stroke Survivors Need to Pay Attention to Bone HealthCategory: Health NewsCreated: 8/9/2019 12:00:00 AMLast Editorial Review: 8/12/2019 12:00:00 AM
Source: MedicineNet Arthritis General - August 12, 2019 Category: Rheumatology Source Type: news

Role of Non ‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) in the Association between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study
ConclusionFindings of this first study to evaluate NSAID's mediating role in OA ‐CVD relationship suggest that NSAID use substantially contributes to the OA‐CVD association.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - August 5, 2019 Category: Rheumatology Authors: Mohammad Atiquzzaman, Mohammad E. Karim, Jacek Kopec, Hubert Wong, Aslam H. Anis Tags: Full Length Source Type: research

A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J. F. Belch, Deborah P. M. Symmons, on behalf of the TRACE RA Consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Pete Tags: Original Article Source Type: research

Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population ‐based cohort study in Taiwan
ConclusionBiologics used in RA patients have been shown to have a beneficial impact on improving clinical outcomes, including decreased risks of death and stroke. The economic burden from costs of biologics may be alleviated by improving outcomes.
Source: International Journal of Rheumatic Diseases - June 24, 2019 Category: Rheumatology Authors: Chao ‐Hsiun Tang, Fun Yu, Ching‐Ya Huang, Der‐Yuan Chen Tags: ORIGINAL ARTICLE Source Type: research

After a Stroke, Your Bones Need Care
Title: After a Stroke, Your Bones Need CareCategory: Health NewsCreated: 4/25/2019 12:00:00 AMLast Editorial Review: 4/25/2019 12:00:00 AM
Source: MedicineNet Arthritis General - April 25, 2019 Category: Rheumatology Source Type: news

Identification of novel Adenosine Deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis
ConclusionOur findings support previous reports that DADA2 has extensive genotypic and phenotypic variability. We suggest that screeningADA2 among children with vasculitic rash, UCV, PAN, or unexplained early ‐onset CNS disease with systemic inflammation may enable an earlier diagnosis of DADA2.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 21, 2019 Category: Rheumatology Authors: Kristen M Gibson, Kimberly A Morishita, Paul Dancey, Paul Moorehead, Britt Dr ögemöller, Xiaohua Han, Jinko Graham, Robert EW Hancock, Dirk Foell, Susanne Benseler, Rashid Luqmani, Rae S M Yeung, Susan Shenoi, Marek Bohm, Alan M Rosenberg, Tags: Full Length Source Type: research

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research

Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis
ConclusionOur findings indicate that ibudilast reduces the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASFs, inhibits Th17 cell responses in vivo, and improves established arthritis. Given the established safety profile of ibudilast in humans, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.
Source: Arthritis and Rheumatology - April 11, 2019 Category: Rheumatology Authors: Felix I. L. Clanchy, Richard O. Williams Tags: Original Article Source Type: research

Correction to: Risk of adverse outcomes in patients with rheumatoid arthritis hospitalized for stroke —a cross-sectional study
The authors of the published version of this article incorrectly presented the affiliation of Li-Chin Sung. The revised affiliation is now presented correctly in this article.
Source: Clinical Rheumatology - April 5, 2019 Category: Rheumatology Source Type: research

Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents
Publication date: Available online 27 February 2019Source: Best Practice & Research Clinical RheumatologyAuthor(s): Fabiola Atzeni, Rossella Talotta, Ignazio Francesco Masala, Maria Chiara Gerardi, Roberto Casale, Piercarlo Sarzi-PuttiniAbstractCentral nervous system (CNS) involvement is quite unusual in patients with rheumatoid arthritis (RA), although cerebral vasculitis, rheumatoid nodules and meningitis have all been reported, and patients with RA may also have CNS comorbidities such as stroke and neuro-degenerative and demyelinating syndromes. It has been found that biological drugs, especially anti-tumour necrosis fa...
Source: Best Practice and Research Clinical Rheumatology - February 28, 2019 Category: Rheumatology Source Type: research

Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study
ConclusionsIn Spain, the prevalence of comorbidities and CV risk factors in RA patients with established and advanced disease is relatively high, and their management in clinical daily practice remains suboptimal.ResumenObjetivosDescribir la prevalencia de comorbilidades en pacientes con AR en España y discutir sobre su manejo en la clínica diaria utilizando los datos de la cohorte española del estudio internacional COMORA.MétodosSubanálisis nacional del estudio COMORA en el que se analizaron las características demográficas y clínicas de 200 pacientes con AR (1987 ACR) y las prácticas rutinarias para el cribado y...
Source: Reumatologia Clinica - February 28, 2019 Category: Rheumatology Source Type: research

Exploring metabolic and inflammatory abnormalities in rheumatoid arthritis patients developing stroke disease: a case-control study using electronic medical record data in northern China
ConclusionsA close monitoring is required for RA patients with dyslipidemia and elevated inflammatory markers, and the primary stroke preventive strategies should be directed against these risk factors.
Source: Clinical Rheumatology - February 7, 2019 Category: Rheumatology Source Type: research